Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer
2019-003857-27Phase 2Completed
- Sponsor
- Radboudumc
- Start
- Dec 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 PSMA I&T in salivary gland cancer (SGC), adenoid cystic carcinoma (ACC) and salivary duct carcinoma (SDC), sponsored by Radboudumc. Primary endpoints: Safety and tolerability and Progression-free survival (PFS). Started Dec 2019; status: completed.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
salivary gland cancer (SGC)adenoid cystic carcinoma (ACC)salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on 2019-003857-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003857-27.